Drug Type T-lymphocyte cell therapy |
Synonyms- |
Target- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Adicet Therapeutics, Inc.Startup |
Active Organization Adicet Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | US | Adicet Therapeutics, Inc.Startup | 21 Oct 2022 |
Solid tumor | Preclinical | US | Adicet Therapeutics, Inc.Startup | 21 Oct 2022 |